Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | CDC25A | P30304 | 1/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.57 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210636 | 0.83 | SMN1; SMN2 (0.61) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL9710185 | 0.83 | SMN1; SMN2 (0.61) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL17962981 | 0.83 | SMN1; SMN2 (0.61) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL8960305 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL9073605 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL15566127 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL6268031 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL1648522 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL5251441 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL2370673 | 0.80 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0935457-B1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0406162-B1 | PROCESS FOR THE PREPARATION OF A NANOEMULSION OF OILPARTICLES IN AN AQUEOUS PHASE | Weder, Hans Georg, Prof. Dr. (CH) | 1993-09-08 | — | — | EP | disclosed |
| US-5152923-A | Mixing triglyceride or fatty acid ester and an amphoteric emulsifier to form alamellar liquid cyr stalline structure and subjecting to high pressure homogenizing | Weder, Hans Georg (CH) | 1992-10-06 | — | — | US | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0406162-A2 | Process for the preparation of a nanoemulsion of oilparticles in an aqueous phase | Weder, Hans Georg, Prof. Dr. (CH) | 1991-01-02 | — | — | EP | disclosed |
| US-4619794-A | Spontaneous preparation of small unilamellar liposomes | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | disclosed |
| EP-0102324-A2 | Lipids and surfactants in an aqueous medium | CIBA-GEIGY AG (CH) | 1984-03-07 | — | — | EP | disclosed |
| EP-0088046-A2 | Lipids in the aqueous phase | CIBA-GEIGY AG (CH) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | LMNA 327/4885ESR1 4104/4885ADORA3 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.